Live Breaking News & Updates on ஆண்டி போரல்

Blueprint Medicines Announces R&D Leadership Transitions
Becker Hewes, M.D., promoted to Chief Medical Officer
Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice President, Clinical Development
Marion Dorsch, Ph.D., Chief Scientific Officer, to depart the company
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company s research and development organization. Effective as of January 11, 2021, Becker Hewes, M.D., currently Senior Vice President, Clinical Development, will succeed Andy Boral, M.D., Ph.D., as Chief Medical Officer, and Dr. Boral will transition to a new role as Executive Vice President, Clinical Development. With his promotion, Dr. Hewes will be responsible for clinical development, clinical operations, pharmacovigilance, translational medicine and bi ....

United States , United Kingdom , Marion Dorsch , Fouad Namouni , Becker Hewes , Blueprint Medicines Corporation , Research Development At Blueprint Medicines , Novartis Institutes For Biomedical Research , Wyeth Pharmaceuticals , Research Development , Georgetown University School Of Medicine , Prnewswire Blueprint Medicines Corporation , Emory Vaccine Center , Vanderbilt University , Clinical Development , Genzyme Corporation , Medicines Corporation , Senior Vice President , Andy Boral , Chief Medical Officer , Executive Vice President , Blueprint Medicines , Chief Scientific Officer , Blueprint Medicine Senior Vice President , Repertoire Immune Medicines , Torque Therapeutics ,